Market Overview

Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences


Pharmaceuticals, Inc.
(NASDAQ:RCKT) ("Rocket"), a leading
U.S.-based multi-platform gene therapy company, today announced that
members of Rocket's executive team will participate in the following
upcoming investor conferences:

  • Citi's 13th Annual Biotech Conference on September 6, 2018
    in Boston, MA
  • Morgan Stanley 16th Annual Global Healthcare Conference on
    September 13, 2018 at 5:15 p.m. Eastern Time in New York, NY

A live audio webcast of the Morgan Stanley fireside chat will be
available on the Investors section of the company's website,
A replay of the presentation will be archived on the Rocket website
following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket") is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket's multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit

View Comments and Join the Discussion!